华菱线缆2连板，中超控股、东方通信、航天长峰、长城电工涨停，创远信科涨超15%，国瓷材料、航 天环宇、亚光科技涨超10%，中钢洛耐、中光防雷、航宇微、天银机电、中环海陆跟涨。 ...

Group 1 - Shanghai's "14th Five-Year Plan" outlines a strategic blueprint for high-quality development, emphasizing innovation and internationalization for local tech companies [1][2] - Companies like Titan Technology, Kasei Biotech, and Yingfang Software are leveraging Shanghai's supportive ecosystem to tackle key technological challenges and expand into global markets [1][2][19] - Kasei Biotech aims to become a pioneer in the global biomanufacturing industry, focusing on high-value utilization of biomass and synthetic biology technologies [4][11][12] Group 2 - Titan Technology has transitioned from a focus on basic manufacturing to a comprehensive production system covering reagents, consumables, and instruments, with significant investments in capacity expansion [19][20][21] - The company has established a full industrial chain and is actively pursuing mergers and acquisitions to enhance its product capabilities and market presence [22][23] - Titan Technology's goal during the "14th Five-Year Plan" is to break into the global market, supported by a strong customer base and ongoing product development [24][25] Group 3 - Yingfang Software has developed a robust disaster recovery system, addressing critical data management needs for various industries, including finance and healthcare [13][14][15] - The company has achieved significant market penetration, serving over 6,000 clients globally, and aims to increase its international revenue share [13][18] - Yingfang Software is focusing on AI integration and international expansion to enhance its competitive edge in the data resilience sector [17][18] Group 4 - Chuangyuan Xinke is advancing communication testing technologies, with a focus on 6G and satellite communication, and has invested heavily in R&D to maintain its competitive position [27][28][29] - The company is expanding its testing capabilities to cover low-altitude and satellite communication, aiming to provide comprehensive testing solutions across various domains [29][30] - Chuangyuan Xinke is also exploring opportunities in the robotics testing sector, recognizing its potential for long-term growth [34][35]

Core Insights - The article discusses significant developments in the pharmaceutical and healthcare industry, including leadership changes, regulatory approvals, and strategic collaborations aimed at enhancing treatment options for patients with complex conditions like brain metastases [14][4][12]. Policy Developments - The National Medical Products Administration (NMPA) is focusing on balancing safety and development, emphasizing the importance of legal administration and scientific regulation to protect the legitimate rights of enterprises and promote high-quality industry development [2]. Drug Approvals - Yuandong Biotech received a drug registration certificate for Brivaracetam tablets, marking it as the first generic drug approved under the new registration classification in China. The expected sales for the original drug are approximately 160,000 yuan in the first half of 2025 [4]. - Jiutian Pharmaceutical has received approval for clinical trials of JMHT06 for treating acute gouty arthritis [5]. Capital Market Activities - L'Oréal plans to increase its stake in Galderma by acquiring an additional 10% of shares, which will raise its total ownership to 20% by early 2026. This move includes the nomination of two non-independent directors from L'Oréal to Galderma's board [7]. Industry Collaborations - Baiyang Pharmaceutical is collaborating with multiple medical institutions to enhance treatment for brain metastases, including launching real-world studies with ZAP-X technology and establishing a precision radiotherapy center [12][9].

Group 1 - The company has received the drug registration certificate for Brexpiprazole tablets from the National Medical Products Administration, marking a significant milestone for the product [1][2] - Brexpiprazole tablets are indicated for the treatment of adult schizophrenia and are classified as a Class 4 chemical drug with a shelf life of 12 months [1][2] - The product is the first domestically approved generic drug under the new registration classification, equivalent to passing the consistency evaluation [2][4] Group 2 - Brexpiprazole was originally developed by Otsuka Pharmaceutical Co., Ltd. and was approved for sale in the U.S. in July 2015, with the product expected to be imported into China by June 2024 [2] - Currently, only the original Otsuka product is available in the domestic market, with sales amounting to approximately 160,000 yuan in the first half of 2025 [2] - The approval of Brexpiprazole tablets is not expected to have a significant impact on the company's recent performance, although uncertainties may arise during the production and sales phase [4]

Core Viewpoint - Yuan Dong Bio has received approval from the National Medical Products Administration for the drug registration certificate of Brupiprazole Tablets [2] Company Summary - The drug approved is named Brupiprazole Tablets, indicating a significant milestone for Yuan Dong Bio in expanding its product portfolio [2]

关于自愿披露布瑞哌唑片获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）于近日收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的《药品注册证书》，现将相关情 况公告如下： 证券代码：688513 证券简称：苑东生物 公告编号：2025-081 成都苑东生物制药股份有限公司 一、药品基本情况 药品名称：布瑞哌唑片 剂型：片剂 规格：1mg、2mg、4mg 注册分类：化学药品 4 类 药品有效期：12 个月 上市许可持有人：成都苑东生物制药股份有限公司 生产企业：成都苑东生物制药股份有限公司 药品注册标准编号：YBH29902025 受理号：CYHS2402228、CYHS2402229、CYHS2402230 证书编号：2025S03610、2025S03611、2025S03612 药品批准文号：国药准字 H20256114、国药准字 H20256115、国药准字 H20256116 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查 ...

Core Viewpoint - Yuan Dong Biotech (688513) has received approval from the National Medical Products Administration for the registration of its drug, Brexpiprazole Tablets, which is indicated for the treatment of adult schizophrenia [1] Company Summary - The approved drug, Brexpiprazole, contains the active ingredient brexpiprazole and is specifically aimed at treating adult patients with schizophrenia [1]

Core Viewpoint - Yuan Dong Biotechnology (688513.SH) has received the drug registration certificate from the National Medical Products Administration (NMPA) for its drug, Brexpiprazole tablets, which are indicated for the treatment of adult schizophrenia [1] Group 1: Product Development - Brexpiprazole tablets contain the active ingredient Brexpiprazole and were originally developed by Otsuka Pharmaceutical Co., Ltd. [1] - The drug was approved for marketing in the United States in July 2015 under the brand name Rexulti® and is expected to be imported into China by June 2024 [1] Group 2: Market Position - Currently, the only available product in the domestic market is the imported original drug, and Yuan Dong's product is the first domestically approved generic drug under the new registration classification, which is considered to have passed the consistency evaluation [1]

Core Viewpoint - The approval of the drug Brupiprazole tablets by the National Medical Products Administration signifies compliance with drug registration requirements, although it is not expected to have a significant impact on the company's recent performance [1] Group 1: Drug Approval Details - The drug name is Brupiprazole tablets, available in dosages of 1mg, 2mg, and 4mg [1] - It is classified as a Class 4 chemical drug with a validity period of 12 months [1] - The active ingredient is Brupiprazole, indicated for the treatment of adult schizophrenia [1] Group 2: Impact on Company Performance - The approval of Brupiprazole tablets is not anticipated to have a major impact on the company's recent financial performance [1]

Market Overview - The market experienced a collective slight decline, with the Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index falling by 0.51%, 0.78%, and 1.12% respectively, as over 3,800 stocks declined and more than 1,400 stocks rose [3] Aerospace Industry - The Zhuque-3 rocket successfully entered orbit but failed its recovery test, which was highly anticipated as a milestone for China's space program, potentially making it the second country after the U.S. to master reusable rocket technology [6][7] - Following the recovery failure, the aerospace sector saw a decline, with stocks like Superjet Co., Qianzhao Optoelectronics, and others experiencing significant drops, while Shanghai Hanxun surged, leading to a partial rebound in the sector [8][9] Consumer Sector - Xiangpiaopiao saw a sudden surge, hitting the daily limit after two rounds of increases, attributed to its popular advertising slogan and the current market trend favoring abstract concepts amid a lack of strong mainstream themes [13][14] - Hebai Group experienced a direct rise in the morning but fell back by the end of the day, closing up 5.42%, driven by the popularity of its products in Guangde, which has sparked a cross-province consumption trend [16] AI and Technology - Zhaoxin Co. announced a new product line related to AI smartphones, but the products were merely cleaning agents, leading to skepticism about the company's marketing strategy [19]